Literature DB >> 15148357

Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing.

Andrew M Siwkowski1, Leila Malik, Christine C Esau, Martin A Maier, Edward V Wancewicz, Klaus Albertshofer, Brett P Monia, C Frank Bennett, Anne B Eldrup.   

Abstract

Cognate recognition between the CD40 receptor and its ligand, CD154, is thought to play a central role in the initiation and propagation of immune responses. We describe the specific down regulation of cell surface associated CD40 protein expression by use of a peptide nucleic acid (PNA) antisense inhibitor, ISIS 208529, that is designed to bind to the 3' end of the exon 6 splice junction within the primary CD40 transcript. Binding of ISIS 208529 was found to alter constitutive splicing, leading to the accumulation of a transcript lacking exon 6. The resulting protein product lacks the transmembrane domain. ISIS 208529-mediated CD40 protein depletion was found to be sequence specific and dose dependent, and was dependent on the length of the PNA oligomer. CD40-dependent induction of IL-12 in primary murine macrophages was attenuated in cells treated with ISIS 208529. Oligolysine conjugation to the PNA inhibitor produced an inhibitor, ISIS 278647, which maintained its specificity and displayed efficacy in BCL1 cells and in primary murine macrophages in the absence of delivery agents. These results demonstrate that PNA oligomers can be effective inhibitors of CD40 expression and hence may be useful as novel immuno-modulatory agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15148357      PMCID: PMC419592          DOI: 10.1093/nar/gkh584

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  29 in total

Review 1.  Molecular mechanisms of action of antisense drugs.

Authors:  S T Crooke
Journal:  Biochim Biophys Acta       Date:  1999-12-10

2.  Synthesis, analysis, purification, and intracellular delivery of peptide nucleic acids.

Authors:  D A Braasch; D R Corey
Journal:  Methods       Date:  2001-02       Impact factor: 3.608

3.  A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells.

Authors:  R J Noelle; M Roy; D M Shepherd; I Stamenkovic; J A Ledbetter; A Aruffo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

4.  Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides.

Authors:  J K Taylor; Q Q Zhang; J R Wyatt; N M Dean
Journal:  Nat Biotechnol       Date:  1999-11       Impact factor: 54.908

5.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

6.  Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs.

Authors:  P Sazani; S H Kang; M A Maier; C Wei; J Dillman; J Summerton; M Manoharan; R Kole
Journal:  Nucleic Acids Res       Date:  2001-10-01       Impact factor: 16.971

7.  Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-alpha chain.

Authors:  J G Karras; M A Maier; T Lu; A Watt; M Manoharan
Journal:  Biochemistry       Date:  2001-07-03       Impact factor: 3.162

8.  Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.

Authors:  R S Geary; T A Watanabe; L Truong; S Freier; E A Lesnik; N B Sioufi; H Sasmor; M Manoharan; A A Levin
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

9.  Regulation of CD40 function by its isoforms generated through alternative splicing.

Authors:  M Tone; Y Tone; P J Fairchild; M Wykes; H Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

10.  Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.

Authors:  R Z Yu; H Zhang; R S Geary; M Graham; L Masarjian; K Lemonidis; R Crooke; N M Dean; A A Levin
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

View more
  11 in total

1.  Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissue.

Authors:  Edward V Wancewicz; Martin A Maier; Andrew M Siwkowski; Klaus Albertshofer; Theodore M Winger; Andres Berdeja; Hans Gaus; Timothy A Vickers; C Frank Bennett; Brett P Monia; Richard H Griffey; Christopher J Nulf; Jiaxin Hu; David R Corey; Eric E Swayze; Garth A Kinberger
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

2.  Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.

Authors:  Takehiko Shiraishi; Jonhard Eysturskarth; Peter E Nielsen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

3.  The Relation Between Thermodynamic and Structural Properties and Cellular Uptake of Peptides Containing Tryptophan and Arginine.

Authors:  Ali Shirani; Javid Shahbazi Mojarrad; Samad Mussa Farkhani; Ahmad Yari Khosroshahi; Parvin Zakeri-Milani; Naser Samadi; Simin Sharifi; Samaneh Mohammadi; Hadi Valizadeh
Journal:  Adv Pharm Bull       Date:  2015-06-01

4.  An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models.

Authors:  Maria A Graziewicz; Teresa K Tarrant; Brian Buckley; Jennifer Roberts; LeShara Fulton; Henrik Hansen; Henrik Ørum; Ryszard Kole; Peter Sazani
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

Review 5.  Targeting RNA splicing for disease therapy.

Authors:  Mallory A Havens; Dominik M Duelli; Michelle L Hastings
Journal:  Wiley Interdiscip Rev RNA       Date:  2013-03-19       Impact factor: 9.957

Review 6.  A chemical view of oligonucleotides for exon skipping and related drug applications.

Authors:  Peter Järver; Liz O'Donovan; Michael J Gait
Journal:  Nucleic Acid Ther       Date:  2013-10-30       Impact factor: 5.486

7.  Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer.

Authors:  Daryl Jin Tai Tay; Yangyang Song; Boya Peng; Tan Boon Toh; Lissa Hooi; Desiree-Faye Kaixin Toh; HuiQi Hong; Sze Jing Tang; Jian Han; Wei Liang Gan; Tim Hon Man Chan; Manchugondanahalli S Krishna; Kiran M Patil; Manikantha Maraswami; Teck Peng Loh; Yock Young Dan; Lei Zhou; Glenn Kunnath Bonney; Pierce Kah-Hoe Chow; Gang Chen; Edward Kai-Hua Chow; Minh T N Le; Leilei Chen
Journal:  Mol Ther       Date:  2021-05-08       Impact factor: 11.454

8.  Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells.

Authors:  John J Turner; Gabriela D Ivanova; Birgit Verbeure; Donna Williams; Andrey A Arzumanov; Saïd Abes; Bernard Lebleu; Michael J Gait
Journal:  Nucleic Acids Res       Date:  2005-11-30       Impact factor: 16.971

9.  Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.

Authors:  Bernard Khoo; Xavier Roca; Shern L Chew; Adrian R Krainer
Journal:  BMC Mol Biol       Date:  2007-01-17       Impact factor: 2.946

10.  Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide.

Authors:  Saïd Abes; John J Turner; Gabriela D Ivanova; David Owen; Donna Williams; Andrey Arzumanov; Philippe Clair; Michael J Gait; Bernard Lebleu
Journal:  Nucleic Acids Res       Date:  2007-06-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.